Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT ID: NCT00259012

Last Updated: 2010-05-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose

Group Type ACTIVE_COMPARATOR

pantoprazole sodium enteric-coated spheroid suspension

Intervention Type DRUG

pediatric suspension taken daily x 7 days

High dose

Group Type ACTIVE_COMPARATOR

pantoprazole sodium enteric-coated spheroid suspension

Intervention Type DRUG

pediatric suspension taken daily x 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pantoprazole sodium enteric-coated spheroid suspension

pediatric suspension taken daily x 7 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than 44 weeks beyond neonatal period but less than 12 months
* Presumptive diagnosis of GERD
* Weight greater than 2.5 kg but less than 15 kg

Exclusion Criteria

* History of gastrointestinal (GI) disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption
* Clinically significant medical or surgical abnormalities
Minimum Eligible Age

1 Month

Maximum Eligible Age

11 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nycomed

INDUSTRY

Sponsor Role collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wyeth

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Australia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Belgium, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For France, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Germany, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Italy, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Poland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Switzerland, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Little Rock, Arkansas, United States

Site Status

Loma Linda, California, United States

Site Status

San Diego, California, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Miami, Florida, United States

Site Status

Pensacola, Florida, United States

Site Status

Chicago, Illinois, United States

Site Status

Park Ridge, Illinois, United States

Site Status

Louisville, Kentucky, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Jackson, Mississippi, United States

Site Status

Kansas City, Missouri, United States

Site Status

New York, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Cleveland, Ohio, United States

Site Status

Temple, Texas, United States

Site Status

Brisbane, , Australia

Site Status

Antwerp, , Belgium

Site Status

Brussels, , Belgium

Site Status

Ghent, , Belgium

Site Status

Paris, , France

Site Status

Aachen, , Germany

Site Status

Osnabrück, , Germany

Site Status

Brescia, , Italy

Site Status

Naples, , Italy

Site Status

Roma, , Italy

Site Status

Krakow, , Poland

Site Status

Lodz, , Poland

Site Status

Lublin, , Poland

Site Status

Warsaw, , Poland

Site Status

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium France Germany Italy Poland Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM. Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease. Clin Pharmacokinet. 2011 Aug;50(8):541-50. doi: 10.2165/11591900-000000000-00000.

Reference Type DERIVED
PMID: 21740077 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3001B3-333, 3001B3-335

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intestinal Microbiota After PPI Treatment
NCT07036627 NOT_YET_RECRUITING